Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Regencell Bioscience Holdings and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Regencell securities between October 28, 2024 and October 31, 2025. The complaint claims the company made false and misleading statements and failed to disclose vulnerability to market manipulation, exposing investors to significant financial risk and heightened regulatory scrutiny. Investors have until June 23, 2026 to seek lead plaintiff appointment. The law firm is handling the case on a contingency fee basis.
Regencell Bioscience Holdings LtdClass action lawsuit alleging securities law violations and false statements.